publication date: Sep. 23, 2016


Sargent, Mayo Biostatistician and Clinical Trialist, Dies Unexpectedly at 46

By Paul Goldberg

Dan Sargent, one of the world’s foremost experts in oncology clinical trials, died unexpectedly on Sept. 22. Sargent died from an acute illness, Mayo officials said. He was 46.

“This is a tremendous loss to Mayo Clinic as well as the national and international cancer research community. Dan has given so much to so many,” said Robert Diasio, director of the Mayo Clinic Cancer Center. “We are deeply saddened by his passing. Our thoughts and prayers are with his wife and family.”

Sargent joined Mayo Clinic Rochester after earning his PhD in biostatistics from the University of Minnesota in 1996. At the time of his death, he was the Ralph S. and Beverley E. Caulkins Professor of Cancer Research, and the Chair of the Division of Biomedical Statistics and Informatics in the Department of Health Sciences Research at the Mayo Clinic.

He was also the principal investigator for the statistics and data management program at the Alliance for Clinical Trials in Oncology.

Monica Bertagnolli, chair of Alliance, said that research group “would not have been created if it were not for Dan’s efforts and particular talents.”

In 2010, Sargent was elected to serve as Group Statistician for Cancer and Leukemia Group B, linking CALGB to the North Central Cancer Treatment Group (The Cancer Letter, Aug. 3, 2010). At the time of this election, NCCTG and ACOSOG had been operating together since 2006, and had partially harmonized their data collection. Sargent said the groups used “two-and-a-half data systems.”

“We have half-way integrated ACSOG and NCCTG,” Sargent said. “We have to finish that and integrate the CALGB system into those that … Continue reading 42-35 Sargent, Mayo Biostatistician and Clinical Trialist, Dies Unexpectedly at 46

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.